CETP as a Therapeutic Target

Title:

CETP as a Therapeutic Target

Topic: Cardiology
Relevant Terms: Novel Therapies In HDL
Primary Audience: This activity has been designed for Cardiologists; Endocrinologist; Internist; Lipidologists; Primary Care Physicians; Physician Assistants; Nurse Practitioners; Pharmacists; Registered Nurses; Registered Dietitians
Launch Date: 11-Oct-12
Credits: 1.5 AMA PRA Category 1 Credits
1.5 ACPE contact hours
1.5 ANCC contact hours
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Explain current research defining the mechanisms underlying cholesteryl ester transfer protein (CETP) inhibition and its impact on HDL metabolism
  2. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families

    Faculty

    Philip Barter, MD, PhD
    Director, The Heart Research Institute
    Professor of Medicine, University of Sydney
    Sydney, Australia

    John J.P. Kastelein, MD PhD, FESC
    Professor of Medicine
    Dept. of Vascular Medicine
    Academic Medical Center / University of Amsterdam
    Amsterdam, The Netherlands
    Stephen Nicholls, MBBS PhD FRACP FACC FESC FAHA
    Professor of Cardiology
    SAHMRI Heart Foundation Heart Disease Theme Leader
    South Australian Health & Medical Research Institute
    Adelaide, SA
    Program Overview
    The Translation of HDL Science Curriculum Slide Library consists of 6 (six) interactive slide lecture note modules that convey the latest evidence and research on HDL and residual risk epidemiology, HDL metabolism, HDL functionality and subfractions, existing HDL raising therapies, novel targets of therapy and therapies in development.  The HDL Slide Library provides slide presentation materials with state of the art, peer-reviewed content developed by International experts in lipidology and HDL research.  These slides efficiently translate the core scientific principles of the HDL curriculum to clinical practice.
     
    This slide module, CETP as a Therapeutic Target, will address the following topics:
     
    Cholesterol Ester Transport Protein: History, Metabolism and Therapeutic Development
    • The Discovery of CETP
    • Functions of Cholesterol Ester Transfer Protein and Relationship to Coronary Artery Disease Risk
    • Genetics of CETP
    • The Effects of CETP Inhibition on Atherosclerosis in Animal Models
    CETP Inhibitors
    • Clinical Trials With CETP Inhibitors
    • Differential Pharmacology of CETP Inhibitor
    • CETP Inhibition:  Lessons Learned and Future Direction
    Activity Format
    Online Enduring
      
    Fee
    There is no fee associated with this activity
     
    Target Audience
    Cardiologists, endocrinologist, internist, lipidologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, registered nurses, registered dietitians and researchers with knowledge and experience in lipid science.
     
    Type of Activity
    Knowledge

    Criteria for Success
    Statements of credit will be awarded based on the participant's successful completion of the post-test with a score of 60% or better and the activity evaluation form. If you have questions about this CME/CE activity, please contact the NLA at cme@lipid.org. Please claim credit by October 11, 2013.
     
    Commercial Support
    This activity is supported by an educational grant from Genentech, USA.

    Credit Designation
     
     
    CME credit provided by the National Lipid Association
     
    Physicians
    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. The National Lipid Association designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
     
    Physician Assistants
    NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
     
    CE Credit provided by Postgraduate Institute for Medicine
     
    Pharmacists
    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number – 0809-9999-12-255-H01-P (Knowledge)
    Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hours (0.01 CEUs) of the Accreditation Council for Pharmacy Education.
     
    Nursing
    This educational activity for 1 contact hours is provided by Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
     
    Dietitians
    This program has been submitted to the Commission on Dietetic Registration (CDR) for 1.5 CPEUs. Contact Postgraduate Institute for Medicine (www.pimed.com) for details.


    FACULTY/PLANNER FINANCIAL DISCLOSURES
    Name
    Relationship
    Company
    Barter, Philip J.
    Advisory Board
    AstraZeneca; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals; Pfizer Inc.; Roche; CSL- Behring
    Speakers Bureau
    AstraZeneca; GlaxoSmithKline; Merck & Co., Inc.; Pfizer, Inc; Roche
    Kastelein, John J.P.
    Advisory Board
    Merck & Co., Inc.; Eli Lilly; AstraZeneca; Boehringer Ingelheim; Omthera; The Medicines Company; Amgen; Resverlogix; Aegerion; Genzyme; Amarin; Isis Pharmaceuticals; Cerenis; Regeneron; Novartis; Sanofi Aventis; Roche
    Consulting
    Merck & Co., Inc.; Eli Lilly; AstraZeneca; Boehringer Ingelheim; Pronova; Omthera; The Medicines Company; Amgen; Alnylam; CSL Behring; Resverlogix; Aegerion; Genzyme; Amarin; VBL Inc; Isis Pharmaceuticals; Cernis; Cardoz; Regeneron; Novartis; Sanofi Aventis; Roche; Kinemed; Xenon
    Speakers Bureau
    Merck & Co., Inc; The Medicines Company; Resverlogix; Genzyme; Isis Pharmaceuticals; Regeneron; Novartis; Roche
    Nicholls, Stephen J.
    Contracted Research
    AstraZeneca; Eli Lily; Resverlogix; Roche; Amgen
    Consultant
    Merck & Co., Inc; CSL Behring; Boehringer Ingelheim
    Speakers Bureau
    AstraZeneca; Roche; Takeda
     
    NLA
    N/A
    Nothing to disclose
    PIM
    N/A
    PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    Disclosure of Unlabeled Use and Investigational Product
     
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclosure Declaration
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
     
    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.

    System Requirements
    To view this educational activity you will need one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac.

    Commercial Support
    This activity is supported by an educational grant from Genentech.